Since HCC is a potential terminal outcome of NAFLD, we compared mRNA expression levels of healthy against HCC tissue for DNTTIP2, ZNF326 and LMO7 next to the published HCC biomarker candidate H2AFY in data from the cancer genome atlas liver hepatocellular carcinoma database (n = 50; Figure 4B, last accessed 29 November 2021). This evidence concerns the gene DNTTIP2 and metabolic dysfunction-associated steatotic liver disease.